

Consolidated Financial Results for the Third Quarter of the Fiscal Year
Ending February 28, 2026 [Japanese GAAP]



January 6 2026

Company name: Hisamitsu Pharmaceutical Co., Inc.
Stock exchange listing: Tokyo, Nagoya, Fukuoka
Securities code: 4530
URL: <https://global.hisamitsu/>
Representative: NAKATOMI Kazuhide, President & CEO
Contact ISOBE Yuichi, Director Executive Officer Head of Corporate Strategy Planning Division
TEL: +81-3-5293-1704
Scheduled date of dividend payment: —
Preparation of supplementary materials for financial results: Yes
Holding of financial results meeting: Yes (for institutional investors and analysts, etc.)

(Amounts are rounded down to the nearest millions of yen)

1. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending February 28, 2026

(March 1, 2025 to November 30, 2025)

(1) Consolidated Operating Results

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended Nov. 30, 2025	114,514	2.9	12,608	(4.6)	16,630	1.0	11,890	(13.0)
Nine months ended Nov. 30, 2024	111,253	8.2	13,220	8.0	16,471	(1.0)	13,660	13.0

(Note) Comprehensive income: Nine months ended Nov. 30, 2025 11,770 millions of yen [(5.9)%]

Nine months ended Nov. 30, 2024 12,502 millions of yen [(55.1)%]

	Profit per share	Diluted profit per share
	yen	yen
Nine months ended Nov. 30, 2025	165.77	165.57
Nine months ended Nov. 30, 2024	185.02	184.76

(2) Consolidated Financial Position

	Total assets	Net assets	Shareholders' equity ratio
As of Nov. 30, 2025	Millions of yen 342,309	Millions of yen 271,614	% 78.5
As of Feb. 28, 2025	343,068	279,407	80.6

(Reference) Shareholders' equity: As of Nov. 30, 2025 268,560 millions of yen

As of Feb. 28, 2025 276,417 millions of yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Fourth quarter	Total
Year ended Feb. 28, 2025	yen —	yen 45.00	yen —	yen 45.00	yen 90.00
Year ending Feb. 28, 2026	—	60.00	—		
Year ending Feb. 28, 2026 (Forecast)				0.00	60.00

(Note) 1. Revisions to the most recently announced dividends forecast: Yes

2. Breakdown of annual dividend forecast for the fiscal year 2025

Ordinary dividend 86.00 yen

Commemorative dividend 4.00 yen (A commemorative dividend for the 90th anniversary of the launch of SALONPAS®)

3. As stated in the "Announcement of Implementation of MBO and Recommendation for Tendering Shares" and "Announcement on Revision of the Dividend Forecast for the Fiscal Year Ending February 28, 2026" announced today (January 6, 2026), the Company's board of directors resolved that the Company's dividend forecast for the fiscal year ending February 28, 2026 be revised and no year-end dividend be paid for the fiscal year ending February 28, 2026, subject to the successful consummation of the tender offer (the "Tender Offer") for our common shares, our stock acquisition rights, and the American Depository Receipts representing our shares issued in the United States by Citibank, N.A.

3. Consolidated Earnings Forecast for the Fiscal Year Ending February 28, 2026 (March 1, 2025 to February 28, 2026)

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Profit per share
Full year	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
	—	—	—	—	—	—	—	—	—

(Note) 1. Revisions to the most recently announced consolidated forecast: Yes

2. As stated in the "Announcement of Implementation of MBO and Recommendation for Tendering Shares" and "Announcement on Withdrawal of the Earnings Forecast for the Fiscal Year Ending February 28, 2026" announced today (January 6, 2026), our common shares are scheduled to be delisted as a result of the Tender Offer and the subsequent series of procedures. Accordingly, we have decided to withdraw and refrain from disclosing the consolidated earnings forecast for the fiscal year ending February 28, 2026.

*Notes

(1) Changes in significant subsidiaries during the period (Changes in specified subsidiaries resulting in changes in scope of consolidation)	: None
(2) Application of special accounting methods for preparation of interim consolidated financial statements	: Yes
(3) Changes in accounting policies, changes in accounting estimates, and restatement	
1) Changes in accounting policies due to revision of accounting standards	: Yes
2) Changes in accounting policies other than 1) above	: None
3) Changes in accounting estimates	: None
4) Restatement	: None
(4) The number of shares outstanding (common stock)	
1) Total number of shares outstanding at the end of the period (including treasury stock)	
As of Nov. 30, 2025	75,164,895 shares
As of Feb. 28, 2025	85,164,895 shares
2) Total number of treasury stock at the end of the period	
As of Nov. 30, 2025	5,091,825 shares
As of Feb. 28, 2025	12,202,127 shares
3) Average number of shares outstanding during the period	
Nine months ended Nov. 30, 2025	71,729,659 shares
Nine months ended Nov. 30, 2024	73,830,845 shares

(Note) The number of treasury stock at the end of the period includes the Company's shares (298,500 shares as of Nov. 30, 2025. 379,600 shares as of Feb. 28, 2025.) held by the "HISAMITSU PHARMACEUTICAL Employee Stockholding Partnership Plan Trust Account". In addition, the Company's shares held by the "HISAMITSU PHARMACEUTICAL Employee Stockholding Partnership Plan Trust Account" are included in the treasury stock deduction in the calculation of the average number of shares during the period (339,267 shares for the nine months ended Nov. 30, 2025. 407,800 shares for the nine months ended Nov 30, 2024).

*Review of the attached quarterly consolidated financial statements by a certified public accountant or an independent auditor: None

*Explanation for appropriate use of financial forecasts and other special notes

As stated in the "Announcement of Implementation of MBO and Recommendation for Tendering Shares" and "Announcement on Withdrawal of the Earnings Forecast for the Fiscal Year Ending February 28, 2026" announced today (January 6, 2026), our common shares are scheduled to be delisted as a result of the Tender Offer and the subsequent series of procedures. Accordingly, we have decided to withdraw and refrain from disclosing the consolidated earnings forecast for the fiscal year ending February 28, 2026.

Financial settlement briefings for institutional investors and analysts will be held on January 7, 2026. Presentation materials of financial results will be posted promptly on the company's website.

Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance sheets

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2025)	Current Third Quarter (As of Nov. 30, 2025)
Assets		
Current assets		
Cash and deposits	114,518	101,418
Notes and accounts receivable - trade, and contract assets	47,223	48,800
Securities	14,598	9,358
Merchandise and finished goods	12,044	14,340
Work in process	794	1,203
Raw materials and supplies	9,553	10,160
Other	5,400	10,541
Allowance for doubtful accounts	(344)	(275)
Total current assets	203,788	195,547
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	29,045	27,769
Other, net	30,854	32,091
Total property, plant and equipment	59,899	59,861
Intangible assets		
Sales rights	300	266
Goodwill	1,294	1,180
Other	4,380	4,107
Total intangible assets	5,974	5,554
Investments and other assets		
Investment securities	60,222	69,115
Other	13,389	12,437
Allowance for doubtful accounts	(207)	(207)
Total investments and other assets	73,405	81,345
Total non-current assets	139,280	146,762
Total assets	343,068	342,309

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2025)	Current Third Quarter (As of Nov. 30, 2025)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	9,910	11,040
Electronically recorded obligations - operating	4,205	6,117
Short-term loans payable	1,065	927
Income taxes payable	3,627	1,412
Provision for bonuses	2,213	980
Other	26,203	31,368
Total current liabilities	47,226	51,848
Non-current liabilities		
Long-term loans payable	1,694	1,431
Net defined benefit liability	7,819	7,816
Other	6,920	9,598
Total non-current liabilities	16,434	18,846
Total liabilities	63,661	70,695
Net assets		
Shareholders' equity		
Capital stock	8,473	8,473
Capital surplus	2,361	2,272
Retained earnings	257,881	223,384
Treasury shares	(47,550)	(20,468)
Total shareholders' equity	221,166	213,662
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	18,485	24,783
Revaluation reserve for land	3,337	3,337
Foreign currency translation adjustment	31,334	25,062
Remeasurements of defined benefit plans	2,093	1,714
Total accumulated other comprehensive income	55,250	54,897
Share acquisition rights	408	333
Non-controlling interests	2,581	2,721
Total net assets	279,407	271,614
Total liabilities and net assets	343,068	342,309

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – Nov. 30, 2024)	Current Fiscal Year (Mar. 1, 2025 – Nov. 30, 2025)
Net sales	111,253	114,514
Cost of sales	44,865	45,279
Gross profit	66,387	69,234
Selling, general and administrative expenses	53,167	56,625
Operating profit	13,220	12,608
Non-operating income		
Interest income	2,172	1,740
Dividend income	822	809
Foreign exchange gains	—	976
Other	592	640
Total non-operating income	3,588	4,167
Non-operating expenses		
Interest expenses	15	15
Share of loss of entities accounted for using equity method	105	28
Foreign exchange losses	173	—
Other	43	100
Total non-operating expenses	337	145
Ordinary profit	16,471	16,630
Extraordinary income		
Gain on disposal of non-current assets	14	3
Gain on sale of investment securities	2,932	137
Total extraordinary income	2,946	141
Extraordinary losses		
Loss on disposal of non-current assets	5	22
Voluntary recall related expenses	—	381
Total extraordinary losses	5	403
Profit before income taxes	19,412	16,368
Income taxes	5,350	4,151
Profit	14,061	12,217
Profit attributable to non-controlling interests	401	326
Profit attributable to owners of parent	13,660	11,890

Quarterly Consolidated Statements of comprehensive income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – Nov. 30, 2024)	Current Fiscal Year (Mar. 1, 2025 – Nov. 30, 2025)
Profit	14,061	12,217
Other comprehensive income		
Valuation difference on available-for-sale securities	(1,534)	6,262
Foreign currency translation adjustment	190	(6,376)
Remeasurements of defined benefit plans, net of tax	(234)	(397)
Share of other comprehensive income of entities accounted for using equity method	19	63
Total other comprehensive income	(1,559)	(446)
Comprehensive income	12,502	11,770
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	12,107	11,537
Comprehensive income attributable to non-controlling interests	395	233



Promoting “TE-A-TE” Culture Worldwide
「手当て」の文化を、世界へ。

